RESULTS
The response rate was 60% (n = 152); 92% of hospitals (n = 140) had locally written CAP guidelines (although in only 100 were policies being used in the emergency department as well as the medical department), 5% (n = 7) used the national BTS CAP guidelines and 3% (n = 5) had no guideline. Sixtyeight guidelines (49%) had been updated in the previous year and 88% (n = 123) had been updated since the BTS 2004 CAP guideline.
Self-reported concerns over healthcare acquired infections influenced local guidelines in 57 hospitals (Clostridium difficile (n = 57), meticillin-resistant Staphylococcus aureus (MRSA) (n = 22)). Other influences included the BTS 2004 guideline (n = 96), cost of antibiotics (n = 26) and local antibiotic profiles (n = 15).
Using severity assessment for planning management was recommended in 94% of guidelines (n = 131/140) including CURB65 tools 3 in 76% (n = 106), CURB 4 in 18, other tools in 9 and clinical judgement only in 9.
First-line antibiotic recommendations for non-severe and severe CAP as stated in local CAP guidelines are shown in table 1. For managing non-severe CAP, 61% of hospitals (n = 85) recommended amoxicillin plus macrolide and 24% (n = 34) recommended amoxicillin alone. For severe CAP, recommended first-line antibiotics were consistent with BTS recommendations in 87% of guidelines (113/130; no data from 10 hospitals) including a b-lactamase stable b-lactam plus a macrolide in 101 and the alternative BTS recommendation of a quinolone and blactam in 12. A simple b-lactam, such as amoxicillin or penicillin, plus a macrolide was recommended in 12 guidelines and other antibiotic choices in 5. In hospitals with C difficile concerns, cephalosporins were less commonly recommended as preferred treatment for CAP than in other hospitals (26% vs 47%, p = 0.01). As alternative therapy for severe CAP, 19% of hospitals (n = 27) recommended b-lactamase stable b-lactam plus macrolide combinations and 36% (n = 51) recommended quinolones (most commonly levofloxacin (n = 33), ciprofloxacin (n = 11) and moxifloxacin (n = 4)), mostly as combination therapy (n = 27). In 35 guidelines no alternative regime was stated, 6 recommended microbiology advice and 21 recommended other choices.
DISCUSSION
This survey of 152 hospitals confirms that UK local guidelines for the management of adult CAP are widespread (but not always used in the emergency department), up-todate, use severity assessment tools and are influenced by both national evidence-based guidelines and local factors, especially healthcare acquired infections, cost and local antibiotic profiles. Compared with 1999, 5 the proportion of hospitals reporting C difficile infection as an influence on local CAP guidelines has increased significantly (from 19% (39/213) in 1999 to 41% (57/140) in 2006; x 2 = 21, p,0.001). The response rate for this survey was only 60%, but there was no obvious difference between responders and non-responders.
This survey confirms the value of having national guidelines for common conditions, which can act as a framework to be adapted for local use.
The role of specialist lung cancer nurses in the UK: a national survey
The role of the lung cancer nurse specialist in the UK is a recent development in response to initiatives aimed at improving the delivery of lung cancer services and it has now become integral to the lung cancer multidisciplinary team (MDT). A small survey in 2000 1 indicated that there was little strategic planning and evaluation of the role, and until recently definition and training requirements have been lacking. Recent guidelines 2 state that all lung cancer units should have at least one specialist lung cancer nurse to support patients and coordinate care between primary and secondary care teams. Despite this, the number, workload and exact duties of these practitioners remain undefined. We therefore conducted a questionnaire survey to determine the current profile of lung cancer nurses working in the UK, which should help plan future roles of these clinical nurse specialists.
A three section questionnaire (focusing on manpower, clinical and non-clinical activities) developed and piloted with members The 125 nurses (66%) working in cancer units carried out more varied duties than those in cancer centres (p,0.01). Table 1 shows the most to the least frequent clinical activities and the degree of involvement by the specialist nurses. Of the non-clinical activities, nearly all (.90%) were involved in education, audit, service and personal development. However, only half were able to carry out research because of a lack of dedicated time and pressure of work. Approximately 50% had management responsibility for other colleagues, and a similar number spent time collecting clinical data for and coordinating the MDT meetings. For a number of nurses, this included populating clinical databases.
Following implementation of the UK National Cancer Plan in the wake of the Calman-Hine Report, 3 there has been a rapid expansion in services aimed at improving the care of lung cancer patients. As part of this, there has been an increase in the number of lung cancer nurses, from 130 in
2000
1 to 250 identified in the current study. The results of our survey show a wide variation in the duties and allocation of lung cancer nurse specialists within cancer services in the UK. Many nurses have a large workload, poorly structured job plans with inadequate secretarial support. Although most were involved in ''front end'' activities, their lack of involvement in the ongoing care of lung cancer patients post diagnosis was disappointing, especially since nurse led follow-up clinics 4 and the establishment of nurse run breathlessness clinics 5 have been shown to be effective means of improving the quality of life for lung cancer patients. Nevertheless, the survey did demonstrate the wide range of services that lung cancer specialist nurses can now provide and there is scope for rolling out these skills to more nurses in more MDTs, easing the burden on hard pressed medical staff. However, the current culture of the NHS makes it difficult for health care commissioners to sanction the appointment of new nurses unless this is linked to an improvement in the achievement of targets, which are not usually quality based. The development of a national job specification tailored to lung cancer patient's needs may help to improve this aspect of care for these patients, and would help commissioners to support this aspect of the Cancer Reform Strategy. 
GOLD stage 1 is crying wolf
Nine out of 10 people with GOLD stage 1 chronic obstructive pulmonary disease (COPD) do not have lung disease and are not at substantially increased risk of developing lung disease during the next decade. The SAPALDIA investigators recently described the outcomes after 11 years of follow-up of 519 adults with GOLD stage 1 COPD, comparing them with 6061 with normal spirometry. 1 More than one-third of these adults, both at the baseline and followup examinations, would have had normal spirometric results if the investigators had used the appropriate lower limit of the normal range for the ratio of the forced expiratory volume in 1 s/forced vital capacity (FEV 1 /FVC) instead of a fixed 0.70, 2 and had taken the time to measure post-bronchodilator spirometry. 3 About half of those with GOLD stage 1 COPD at the baseline examination (N = 224) reported either a chronic cough, chronic phlegm, chronic bronchitis or dyspnoea. However, in adults with a normal FEV 1 (especially in neversmokers), these non-specific symptoms are usually not due to COPD. A chronic cough is often due to gastro-oesophageal reflux (often due to obesity) or asthma (not yet diagnosed by a doctor). Chronic phlegm is often due to rhinosinusitis with postnasal drainage. Dyspnoea with a normal FEV 1 is usually due to cardiac deconditioning, obesity or over-reporting, and sometimes is 
